πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

522 results for β€œtherapy” Clear

  1. KISIMA-02 vaccine-based immunotherapy for patients with pancreatic cancer

    Boehringer Ingelheim

    G12D/G12V Pancreatic Ductal Adenocarcinoma

    phase 1 other active

    1 trial

  2. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

    Kura Oncology

    Pancreatic Ductal Adeno Carcinoma, Colorectal Cancer, Non- Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma

    phase 1 other active

    1 trial

  3. KYV-101 anti-CD19 CAR-T cell therapy

    Kyverna Therapeutics

    Multiple Sclerosis

    phase 1 mab active

    1 trial

  4. LCAR-B4822M CAR-T Cell Immunotherapy

    Nanjing Legend Biotech Co.

    Refractory or Relapsed Multiple Myeloma

    phase 1 small molecule active

    1 trial

  5. Low Level Laser Therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Orthodontic Appliance Complication

    phase 1 other completed

    1 trial

  6. MCA-derived MSC therapy in renal transplant recipients

    Disc Medicine

    Rejection transplanted kidney, BPAR

    phase 1 other active

    1 trial

  7. Mindful Awareness in Body-oriented Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorder

    phase 1 other completed

    1 trial

  8. NY-ESO-1（TCR Affinity Enhancing Specific T cell TherapyοΌ‰

    Chongqing Precision Biotech Co., Ltd

    Bone Sarcoma

    phase 1 mab active

    1 trial

  9. Neoadjuvant chemotherapy

    Hospital Authority, Hong Kong

    Squamous Cell Carcinoma of Oral Cavity

    phase 1 small molecule completed

    1 trial

  10. Nicotine Replacement Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 1 small molecule completed

    1 trial

  11. Nimotuzumab and chemotherapy

    Biotech Pharmaceutical Co.,

    Non-small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  12. Novel Supplement Based Therapy

    Atrium Therapeutics

    Small Intestinal Bacterial Overgrowth

    phase 1 other terminated

    1 trial

  13. Phase 1 First in Human Study to Explore AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

    Amgen

    Dose Escalation: Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric cancer (GC), melanoma (MEL). Dose Confirmation: Lead Indication based on data from dose escalation. Dose Expansion: Tertiary Lymphoid Structure positive (TLS+) CRC, GC, and NSCLC.

    phase 1 other active

    1 trial

  14. Phase 1 Study of Revumenib in Combination with Intensive Chemotherapy in Participants with AML Harboring Alterations in KMT2A/MLL, NPM1, or NUP98 Genes

    Syndax Pharmaceuticals

    Acute Myeloid Leukemias

    phase 1 other active

    1 trial

  15. Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors.

    Revolution Medicines

    Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor, Colorectal Cancer (CRC)

    phase 1 other active

    1 trial

  16. Phase 1b Study of Dato-DXd in Combination with Pembrolizumab with or without Platinum Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer

    Daiichi Sankyo

    Non-small cell lung cancer

    phase 1 other active

    1 trial

  17. Phase 1b safety study of xevinapant, weekly cisplatin, and radiotherapy in participants with unresected LA SCCHN

    Merck Sharp and Dohme

    Locally Advanced Squamous Cell Carcinoma of the Head and Neck

    phase 1 other active

    1 trial

  18. Phase Ib Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy in PAH (SEASIDE)

    Lacuna Pharma Pty Ltd

    Pulmonary arterial hypertension

    phase 1 other active

    1 trial

  19. Pilot Study on Subcutaneously Administered Immunotherapy for the Treatment of Cervical Cancer

    Disc Medicine

    Cervical Cancer

    phase 1 other active

    1 trial

  20. RESTART; Autologous Transplantation of Adult Salivary Gland Stem Cells to Restore Submandibular Gland Function after Radiotherapy

    Disc Medicine

    Patients operated with curative intend for head and neck cancer with an indication for bilateral postoperative radiotherapy, with or without chemotherapy.

    phase 1 other active

    1 trial

  21. Regorafenib in combination with temozolomide with or without radiotherapy in patients with newly diagnosed MGMT-Methylated, IDH wild-type glioblastoma. A phase I dose-finding study (REGOMA-2).

    Istituto Gentili S.r.l.

    MGMT-Methylated, IDH wild-type glioblastoma

    phase 1 other active

    1 trial

  22. Safety and Early Signs of Efficacy of IL12-L19L19

    Philogen S.p.A.

    Advanced or metastatic carcinomas after previous immune checkpoint blockade therapy

    phase 1 other active

    1 trial

  23. Sonodynamic therapy (SDT)

    The First People's Hospital of Lianyungang

    Carotid Atherosclerosis

    phase 1 other completed

    1 trial

  24. Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

    Merck Sharp and Dohme

    Advanced Pancreatic cancer, Unresectable Glioblastoma and Variants, PD-1-exposed Advanced/Met HNSCC, Advanced/Met HNSCC, Advanced/Met NSCLC, Advance/Met RCC, Advanced/Met Gastric or GEJ adenocarcinoma, Ovarian Cancer. TNBC, Advanced Mesothelioma, Advanced Solid tumors(coformulation)

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources